Points to Consider for Implementation of the ICH E17 Guideline: Learning from Past Multiregional Clinical Trials in Japan
Authors:
Open Access
- 27 November 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 109 (6) , 1555-1563
Abstract
We identified the major points that are described in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E17 guideline but have not been considered in the past multiregional clinical trials (MRCTs) used for drug approval in Japan to elucidate potential challenges in the implementation of the ICH E17 guideline in Japan. Based on the analysis of 167 MRCTs of 130 drugs, several points, such as the same dose setting and consistency between the overall and Japanese populations, in addition to good clinical practice compliance, have been well considered in ≥ 75% of MRCTs. In contrast, the use of relevant guidelines for disease and primary end point definitions, standardization of efficacy/safety information, sample size allocation, as well as training/validation on subject selection and primary end point, have been addressed less adequately and may need to be considered when planning future MRCTs. This study provides useful information for the implementation of the ICH E17 guideline in Japan.Keywords
Funding Information
- Japan Agency for Medical Research and Development
- Ministry of Health, Labour and Welfare
This publication has 9 references indexed in Scilit:
- Factors Affecting Drug‐Development Strategies in Asian Global Clinical Trials for Drug Approval in JapanClinical and Translational Science, 2017
- Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in JapanThe Journal of Clinical Pharmacology, 2014
- Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanClinical Pharmacology & Therapeutics, 2013
- Regulatory Challenges in the Review of Data from Global Clinical Trials: The PMDA PerspectiveClinical Pharmacology & Therapeutics, 2013
- Regulatory and Scientific Issues Regarding Use of Foreign Data in Support of New Drug Applications in the United States: An FDA PerspectiveClinical Pharmacology & Therapeutics, 2013
- Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug DevelopmentDrug Metabolism and Pharmacokinetics, 2012
- Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response FactorsClinical Pharmacology & Therapeutics, 2010
- Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian PopulationsClinical Pharmacology & Therapeutics, 2008
- A haplotype map of the human genomeNature, 2005